Axsome Therapeutics (AXSM) Retained Earnings (2015 - 2026)
Axsome Therapeutics recorded quarterly Retained Earnings of -$1.4 billion in Q1 2026, down 4.94% quarter-over-quarter from -$1.3 billion in Q4 2025, and down 15.93% year-over-year from -$1.6 billion in Q1 2025.
Axsome Therapeutics' Retained Earnings history runs 12 years deep, the most recent figure standing at -$1.4 billion for Q1 2026.
- In Q1 2026, Retained Earnings fell 15.93% year-over-year to -$1.4 billion; the TTM figure through Mar 2026 stood at -$1.4 billion (down 15.93% YoY), while the FY2025 annual figure was -$1.3 billion, down 16.31% from the prior year.
- Retained Earnings came in at -$1.4 billion for Q1 2026 at Axsome Therapeutics, down from -$1.3 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$448.8 million in Q1 2022 to a low of -$1.4 billion in Q1 2026.
- A 5-year average of -$902.9 million and a median of -$903.9 million in 2024 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings plunged 48.78% in 2024 and dropped 15.93% in 2026, its largest moves.
- Axsome Therapeutics' Retained Earnings stood at -$596.3 million in 2022, then slumped by 40.12% to -$835.6 million in 2023, then tumbled by 34.37% to -$1.1 billion in 2024, then slipped by 16.31% to -$1.3 billion in 2025, then decreased by 4.94% to -$1.4 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$1.4 billion, -$1.3 billion, and -$1.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | -1.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.37 Bn |
| Dec 31, 2025 | -1.31 Bn |
| Sep 30, 2025 | -1.28 Bn |
| Jun 30, 2025 | -1.23 Bn |
| Mar 31, 2025 | -1.18 Bn |
| Dec 31, 2024 | -1.12 Bn |
| Sep 30, 2024 | -1.05 Bn |
| Jun 30, 2024 | -983.30 Mn |
| Mar 31, 2024 | -903.90 Mn |
| Dec 31, 2023 | -835.57 Mn |
| Sep 30, 2023 | -736.92 Mn |
| Jun 30, 2023 | -674.70 Mn |
| Mar 31, 2023 | -607.55 Mn |
| Dec 31, 2022 | -596.33 Mn |
| Sep 30, 2022 | -535.10 Mn |
| Jun 30, 2022 | -490.30 Mn |
| Mar 31, 2022 | -448.83 Mn |
| Dec 31, 2021 | -409.20 Mn |
| Sep 30, 2021 | -375.20 Mn |
| Jun 30, 2021 | -340.30 Mn |
| Mar 31, 2021 | -308.06 Mn |
| Dec 31, 2020 | -278.80 Mn |
| Sep 30, 2020 | -249.60 Mn |
| Jun 30, 2020 | -226.71 Mn |
| Mar 31, 2020 | -208.38 Mn |
| Dec 31, 2019 | -175.90 Mn |
| Sep 30, 2019 | -151.10 Mn |
| Jun 30, 2019 | -132.00 Mn |
| Mar 31, 2019 | -118.19 Mn |
| Dec 31, 2018 | -107.55 Mn |
| Sep 30, 2018 | -97.95 Mn |
| Jun 30, 2018 | -89.67 Mn |
| Mar 31, 2018 | -81.39 Mn |
| Dec 31, 2017 | -76.58 Mn |
| Sep 30, 2017 | -69.15 Mn |
| Jun 30, 2017 | -62.72 Mn |
| Mar 31, 2017 | -55.64 Mn |
| Dec 31, 2016 | -47.64 Mn |
| Sep 30, 2016 | -40.31 Mn |
| Jun 30, 2016 | -33.12 Mn |
| Mar 31, 2016 | -26.31 Mn |
| Dec 31, 2015 | -20.44 Mn |